Profile data is unavailable for this security.
About the company
BioInvent International AB is a Sweden-based biopharmaceutical company, that develops antibody-based drugs for cancer therapies, with two ongoing programs in Phase l/ll clinical trials for the treatment of haematological cancer and solid tumors. The Company’s operational activities are focused on expanding the clinical development of human antibodies, such as BI-1206, BI-1808, BI-1607 and BT-001. The Company has one wholly-owned subsidiary BioInvent Finans AB, which engaged in the administration of warrants issued by the Company.
- Revenue in SEK (TTM)71.46m
- Net income in SEK-330.30m
- Incorporated1997
- Employees111.00
- LocationBioInvent International ABThe Gamma Building, Ideongatan 1LUND 223 70SwedenSWE
- Phone+46 462868550
- Fax+46 462110806
- Websitehttps://www.bioinvent.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Moberg Pharma AB (publ) | 0.00 | -21.09m | 941.99m | -- | -- | 1.52 | -- | -- | -1.20 | -1.20 | 0.00 | 21.84 | 0.00 | -- | -- | -- | -3.52 | -- | -3.66 | -- | -- | -- | -- | -- | 3.04 | -- | 0.0077 | -- | -100.00 | -- | -34.26 | -- | -- | -- |
| XSpray Pharma AB (publ) | 0.00 | -179.67m | 1.01bn | 26.00 | -- | 1.82 | -- | -- | -7.02 | -7.02 | 0.00 | 22.19 | 0.00 | -- | -- | 0.00 | -26.60 | -18.38 | -28.03 | -19.26 | -- | -- | -- | -- | 4.36 | -- | 0.0504 | -- | -- | -- | -36.45 | -- | 2.87 | -- |
| Vistin Pharma ASA | 433.66m | 45.16m | 1.05bn | 79.00 | 23.22 | 3.28 | 16.82 | 2.42 | 1.03 | 1.03 | 9.88 | 7.28 | 1.09 | 2.16 | 7.75 | -- | 11.33 | 1.73 | 14.64 | 2.11 | 59.70 | 59.01 | 10.41 | 2.36 | 1.30 | 6.81 | -- | -- | 52.37 | 17.11 | 1,067.85 | -- | -0.2357 | -- |
| Cereno Scientific AB | 0.00 | -48.11m | 1.13bn | 5.00 | -- | 4.36 | -- | -- | -0.241 | -0.241 | 0.00 | 0.9258 | 0.00 | -- | -- | 0.00 | -19.22 | -16.81 | -20.75 | -18.26 | -- | -- | -- | -- | -- | -12.92 | 0.1734 | -- | -- | -- | -73.95 | -- | 44.79 | -- |
| Infant Bacterial Therapeutics AB | 0.00 | -123.07m | 1.14bn | 8.00 | -- | 3.88 | -- | -- | -9.90 | -9.90 | 0.00 | 22.65 | 0.00 | -- | -- | 0.00 | -35.11 | -16.11 | -38.65 | -16.69 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -88.03 | -- | -- | -- |
| SyntheticMR AB (publ) | 89.21m | 10.01m | 1.19bn | 37.00 | 116.56 | 10.18 | 73.09 | 13.32 | 0.2445 | 0.2445 | 2.17 | 2.80 | 0.6599 | -- | 1.61 | 2,411,162.00 | 7.41 | 7.19 | 8.89 | 8.85 | 105.78 | 106.74 | 11.22 | 9.08 | -- | 14.13 | 0.0107 | 21.50 | 30.67 | 13.05 | 70.34 | -7.33 | 26.79 | -- |
| Diamyd Medical AB | 282.00k | -120.18m | 1.21bn | 26.00 | -- | 6.23 | -- | 4,280.08 | -1.41 | -1.41 | 0.0033 | 1.91 | 0.0014 | -- | 6.56 | 11,280.00 | -59.77 | -25.46 | -66.19 | -28.37 | -4,930.85 | -1,419.23 | -42,617.73 | -5,896.43 | -- | -130.78 | 0.1176 | -- | 20.26 | -5.54 | -12.13 | -- | -- | -- |
| Arcticzymes Technologies ASA | 117.67m | 18.52m | 1.31bn | 61.00 | 70.24 | 4.29 | 52.68 | 11.12 | 0.3702 | 0.3702 | 2.35 | 6.07 | 0.3618 | 0.5941 | 2.43 | -- | 5.69 | 15.52 | 6.12 | 17.16 | 95.02 | 96.69 | 15.74 | 33.10 | 12.43 | -- | 0.0392 | -- | -13.16 | 12.24 | -43.02 | -- | 47.93 | -- |
| Hansa Biopharma AB | 165.88m | -844.88m | 1.44bn | 166.00 | -- | -- | -- | 8.67 | -16.07 | -16.07 | 3.15 | -7.10 | 0.1424 | 64.03 | 1.86 | 987,386.90 | -72.51 | -47.96 | -92.27 | -56.12 | 56.80 | 64.18 | -509.33 | -835.04 | 2.55 | -9.65 | 1.65 | -- | -13.22 | 109.06 | -36.09 | -- | -35.24 | -- |
| Photocure ASA | 495.32m | 264.15k | 1.49bn | 106.00 | 7,715.88 | 3.11 | 53.74 | 3.00 | 0.0072 | 0.0072 | 18.58 | 17.79 | 0.7001 | 0.8203 | 9.37 | -- | 0.0375 | -3.09 | 0.0429 | -3.56 | 94.78 | 93.64 | 0.0535 | -5.19 | 4.32 | -- | 0.00 | -- | 27.35 | 22.50 | 100.37 | -- | 49.83 | -- |
| BioInvent International AB | 71.46m | -330.30m | 1.65bn | 111.00 | -- | 1.26 | -- | 23.16 | -5.02 | -5.02 | 1.09 | 19.90 | 0.0459 | -- | 5.16 | 643,792.80 | -21.23 | -17.50 | -22.40 | -18.64 | -- | -- | -462.22 | -131.63 | 14.77 | -- | 0.0174 | -- | -78.09 | 13.14 | -677.13 | -- | 28.17 | -- |
| Egetis Therapeutics AB (publ) | 57.50m | -326.80m | 1.68bn | 27.00 | -- | 3.08 | -- | 29.26 | -1.28 | -1.28 | 0.224 | 1.86 | 0.087 | 16.92 | 3.59 | 2,129,630.00 | -49.44 | -33.02 | -55.92 | -36.46 | 80.87 | -- | -568.00 | -357.72 | 3.32 | -- | 0.1688 | -- | 154.87 | 15.35 | -68.68 | -- | -- | -- |
| Devyser Diagnostics AB | 169.30m | -53.60m | 1.71bn | 118.00 | -- | 4.44 | -- | 10.10 | -3.31 | -3.31 | 10.46 | 23.65 | 0.335 | 1.59 | 5.53 | 1,434,746.00 | -10.65 | -8.97 | -12.00 | -10.15 | 85.53 | 80.14 | -31.78 | -23.91 | 5.11 | -- | 0.1626 | -- | 33.71 | 28.59 | -16.64 | -- | 44.59 | -- |
| Genovis AB | 158.23m | 61.50m | 1.87bn | 37.00 | 30.34 | 9.78 | 26.20 | 11.79 | 0.9394 | 0.9394 | 2.42 | 2.91 | 0.7203 | -- | -- | 4,276,514.00 | 27.99 | 18.56 | 30.74 | 21.45 | 72.20 | 65.51 | 38.87 | 23.88 | -- | -- | -- | -- | 54.54 | 35.56 | 449.56 | -- | -- | -- |
| Vicore Pharma Holding AB | 0.00 | -310.94m | 1.93bn | 24.00 | -- | 4.24 | -- | -- | -3.24 | -3.24 | 0.00 | 4.08 | 0.00 | -- | -- | 0.00 | -74.40 | -58.65 | -83.09 | -65.58 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -7.81 | -- | -- | -- |
| Nanoform Finland Oyj | 29.97m | -242.46m | 1.97bn | 165.00 | -- | 2.52 | -- | 65.89 | -0.2674 | -0.2674 | 0.0331 | 0.8535 | 0.0287 | 138.93 | 4.11 | 15,548.42 | -23.22 | -27.13 | -25.12 | -29.48 | -507.09 | -604.26 | -809.08 | -1,023.70 | 8.16 | -- | 0.0964 | -- | -26.41 | 61.31 | 5.98 | -- | 53.92 | -- |
Data as of Apr 26 2024. Currency figures normalised to BioInvent International AB's reporting currency: Swedish Krona SEK
36.04%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Redmile Group LLCas of 30 Jun 2023 | 10.13m | 15.39% |
| HBM Partners AG (Investment Management)as of 31 Dec 2023 | 5.14m | 7.80% |
| Fj�rde AP-fondenas of 31 Dec 2023 | 4.02m | 6.11% |
| Handelsbanken Fonder ABas of 31 Mar 2024 | 1.44m | 2.19% |
| Swedbank Robur Fonder ABas of 29 Feb 2024 | 1.28m | 1.94% |
| E. �hman J :or Fonder ABas of 29 Feb 2024 | 551.07k | 0.84% |
| Rhenman & Partners Asset Management ABas of 30 Jun 2023 | 450.00k | 0.68% |
| Skandia Investment Management ABas of 29 Feb 2024 | 325.96k | 0.50% |
| SEB Investment Management ABas of 28 Mar 2024 | 325.89k | 0.50% |
| Dimensional Fund Advisors LPas of 31 Jan 2024 | 54.92k | 0.08% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
